ZyVersa Therapeutics Shares Are Trading Higher After the Company Announced IRB Approval of the Phase 2a Clinical Trial Protocol to Evaluate the Efficacy and Safety of Cholesterol Efflux Mediator VAR 200 in Patients With Diabetic Kidney Disease
ZyVersa Therapeutics宣布IRB批准2a期临床试验协议,以评估胆固醇外流介质VAR 200对糖尿病肾脏病患者的疗效和安全性,此后,该公司股价走高